Australia markets closed

Grifols, S.A. (GIFLF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
9.88-1.27 (-11.39%)
At close: 10:30AM EDT

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 935 712 200
https://www.grifols.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees23,000

Key executives

NameTitlePayExercisedYear born
Mr. Thomas H. GlanzmannExecutive Chairman2.06MN/A1958
Mr. Jose Ignacio Abia BuenacheCEO & DirectorN/AN/A1968
Mr. Alfredo Arroyo GuerraCFO & VPN/AN/A1958
Mr. Lluis Pons GomezSenior Vice President of Strategy & COO OfficeN/AN/A1983
Ms. Nuria Pascual LapeñaVP of Corporate Treasury, Risk Management Investor Relation & Sustainability OfficerN/AN/A1964
Mr. David Ian BellChief Corporate Development, Legal & Data Protection OfficerN/AN/A1954
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/AN/A1965
Mr. Camille AlpiChief Human Resources & Talent OfficerN/AN/A1981
Mr. Vicente Blanquer TorreChief Quality OfficerN/AN/A1961
Mr. Sergio Roura AdellPresident of Commercial Tech SupportN/AN/A1968
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Corporate governance

Grifols, S.A.’s ISS governance QualityScore as of 1 May 2024 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 9; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.